CMS Issues List Of Potential National Coverage Determination Topics
This article was originally published in The Gray Sheet
Most of the 33 items or services in the list have implications for manufacturers of medical devices, combination products or diagnostics.
You may also be interested in...
The agency affirms the evidence in favor of implantable defibrillators for primary prevention of sudden cardiac death is strong for patients with reduced left-ventricular ejection fraction, but does not support resynchronization ICDs for this population.
Breast cancer tests are the most common among the new genetic tests to emerge since 2011, an Agency for Healthcare Research and Quality report finds.
Medical imaging manufacturers and professional societies echoed Eli Lilly’s criticism of the CMS proposal to cover beta-amyloid PET for use in patients suffering from dementia and neurodegenerative disease.